Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Sangamo"


4 mentions found


Crypto stocks – Stocks tied to the price of bitcoin gained as the cryptocurrency inched higher on Tuesday. The conglomerate added 76,487 more shares of Verisign over the past three trading days for 15.6 million. Sangamo Therapeutics – Shares of Sangamo Therapeutics plunged more than 54% after the company said its partner Pfizer ended their hemophilia A gene therapy co-development agreement , delaying the prospects of bringing the development to market. EQT – The energy company gained less than 1% a day after announcing the closing of a midstream joint venture with Blackstone Credit & Insurance . Super Micro Computer – Shares gained more than 1% after closing the previous session as the worst performer in the S & P 500, falling around 4%.
Persons: Stocks, bitcoin, Warren, Berkshire Hathaway, Pfizer, EQT, , Alex Harring, Yun Li, Pia Singh, Lisa Kailai Han Organizations: Miners Mara Holdings, Sangamo Therapeutics, Pfizer, Blackstone Credit & Insurance, Nvidia, Dow Jones Locations: Verisign, Blackstone
Check out the companies making headlines in midday trading: Intel — The struggling chip stock bounced into year-end, rising close to 1.2% in midday trading. Intel has plunged more than 60% in 2024, making the stock poised to see its worst year on record and be the second-worst performer in the S & P 500 . Nvidia — The artificial intelligence giant and retail investor favorite shed 1.3% as traders took profits as the trading year wraps up. With a rally of more than 170%, Nvidia is poised to be the third-best performer in the S & P 500 for 2024. Biohaven — The biopharmaceutical stock popped nearly 2% after director John Childs disclosed a purchase of 29,000 shares.
Persons: Sangamo, John Childs, Childs, Nutriband, Mark Strome, — CNBC's Sean Conlon, Yun Li, Pia Singh Organizations: Intel, Nvidia, Sangamo Therapeutics, Pfizer, Zivo Locations: Macao
Pfizer on Wednesday said its experimental gene therapy for a rare genetic blood-clotting disorder succeeded in a large late-stage trial, paving the way for a potential approval. Without enough of that protein, the blood cannot clot properly, increasing the risk of spontaneous bleeding and severe bleeding after surgery. Pfizer said its one-time treatment significantly cut the number of annual bleeding episodes in patients with moderately severe to severe hemophilia A after 15 months. If approved, Pfizer's therapy will compete with BioMarin Pharmaceutical 's one-time treatment Roctavian. BioMarin is reportedly considering whether to divest its hemophilia A therapy, which costs $2.9 million.
Persons: Andrew Leavitt, Pfizer Organizations: Pfizer, Sangamo Therapeutics, BioMarin Locations: U.S
Top SVB depositors got letters from Sen. Elizabeth Warren and Rep. Alexandria Ocasio-Cortez. "Silicon Valley Bank's unusually cozy relationship with its clients increased the threat of contagion when the bank went under." The Democrats representing Massachusetts and New York on Sunday sent letters to 14 of SVB's largest depositors about a month after SVB's implosion, the report said. "Silicon Valley Bank's unusually cozy relationship with its clients increased the threat of contagion when the bank went under," Warren told Bloomberg in a statement. Warren and Ocasio-Cortez also sent letters to BILL, Eiger, Ginkgo Bioworks, iRhythm Technologies, LendingClub, Oncorus, Payoneer Global, Protagonist Therapeutics, Rocket Lab USA, and Sangamo Therapeutics.
Total: 4